Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 4 institutions in 1 country.
Patricia Nefertari Ramírez-FloresCentro de Investigación Biomédica del Noreste, Departamento de Biología Molecular, Instituto Mexicano del Seguro Social, Monterrey 64720, Mexico.
Paulina J Barraza-ReynaCentro de Investigación Biomédica del Noreste, Departamento de Biología Molecular, Instituto Mexicano del Seguro Social, Monterrey 64720, Mexico.
Alain Aguirre-VázquezCentro de Investigación Biomédica del Noreste, Departamento de Biología Molecular, Instituto Mexicano del Seguro Social, Monterrey 64720, Mexico.ORCID 0000-0002-1147-1428
María E Camacho-MollCentro de Investigación Biomédica del Noreste, Departamento de Biología Molecular, Instituto Mexicano del Seguro Social, Monterrey 64720, Mexico.
Carlos Enrique Guerrero-BeltránTecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey 64710, Mexico.ORCID 0000-0002-5001-0093
Diana Resendez-PérezDepartamento de Biología Celular y Genética, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza 66451, Mexico.
Vianey González-VillasanaDepartamento de Biología Celular y Genética, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza 66451, Mexico.
Jesús Norberto Garza-GonzálezDepartmento de Ciencias Básicas, Vicerrectoría en Ciencias de la Salud, Universidad de Monterrey, San Pedro Garza García 66238, Mexico.
Beatriz Silva-RamírezCentro de Investigación Biomédica del Noreste, Departamento de Inmunogenética, Instituto Mexicano del Seguro Social, Monterrey 64720, Mexico.ORCID 0000-0001-6262-7843
Fabiola Castorena-TorresTecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey 64710, Mexico.ORCID 0000-0002-1157-0004
Mario Bermúdez de LeónCentro de Investigación Biomédica del Noreste, Departamento de Biología Molecular, Instituto Mexicano del Seguro Social, Monterrey 64720, Mexico.ORCID 0000-0002-0993-2969
Mexican Social Security Institute · MXTecnológico de Monterrey · MXUniversidad Autónoma de Nuevo León · MXUniversity of Monterrey · MX
Funding
Instituto Mexicano del Seguro Social FIS/IMSS/PROT/G17-2/1746
6 · The paper itself
Abstract
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. The number of cases is increasing and the trend for the next few years is not encouraging. HCC is usually detected in the advanced stages of the disease, and pharmacological therapies are not entirely effective. For this reason, it is necessary to search for new therapeutic options. The objective of this work was to evaluate the effect of the drugs isotretinoin and thalidomide on
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Isotretinoin and Thalidomide Down-Regulate · full record | OpenQuestion